<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578368</url>
  </required_header>
  <id_info>
    <org_study_id>RENAISSANCE</org_study_id>
    <nct_id>NCT02578368</nct_id>
  </id_info>
  <brief_title>Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction</brief_title>
  <acronym>FLOT5</acronym>
  <official_title>Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft für Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previously untreated patients with limited metastatic stage (see protocol for details on&#xD;
      criteria) will receive 4 cycles of FLOT (5-Fluorouracil, Leucovorin, Oxaliplatin and&#xD;
      Docetaxel). Patients without disease progression will be randomized 1:1 to receive additional&#xD;
      chemotherapy cycles (4-8 cycles of FLOT) or surgical resection followed by subsequent&#xD;
      chemotherapy (4-8 cycles of FLOT). Main objective of the study is overall survival. Most&#xD;
      important secondary objective is the quality of life under treatment and during follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with potentially limited metastatic gastric cancer or adenocarcinoma of the&#xD;
      gastroesophageal junction (GEJ) potentially fulfilling the selection criteria and who gave&#xD;
      informed consent will undergo a careful screening and a central review process. 271 patients&#xD;
      are to be allocated to the trial, of which at least 176 patients will be randomized. The&#xD;
      primary objective is to extend overall survival, while preserving quality of life. The study&#xD;
      has an 80% power to detect a statistically significant improvement (hazard ratio, HR 0.65) in&#xD;
      overall survival in favor of the bimodal strategy. Quality of life (QoL) under treatment and&#xD;
      during follow-up represents the most important secondary endpoint.&#xD;
&#xD;
      All patients enrolled will receive four cycles (= 8 weeks) of FLOT. For HER-2 (human&#xD;
      epidermal growth factor receptor 2) positive disease, trastuzumab should be added.&#xD;
&#xD;
      After the 4th cycle of FLOT, patients will undergo a repeated imaging&#xD;
      (esophago-gastro-duodenoscopy, CT/MRI or PET scan of the involved organs). Patients with&#xD;
      disease progression will be taken out of the trial. Patients with stable disease, partial or&#xD;
      complete remission will be stratified by tumor location (gastric vs. GEJ adenocarcinoma),&#xD;
      response to preoperative FLOT (complete or partial remission vs. stable disease) and based on&#xD;
      whether they have distant lymph node metastases only or additional organ involvement and will&#xD;
      be randomized 1:1 to Arm A (with surgery) or B (no surgery).&#xD;
&#xD;
      Arm A:&#xD;
&#xD;
      Surgery will be scheduled 4-6 weeks after d1 of the last cycle of preoperative chemotherapy&#xD;
      (d1 + 4-6 weeks). The protocol gives detailed recommendations for resection of the primary&#xD;
      tumor as well as the metastases. Post-operatively, further 4-8 cycles of FLOT can be&#xD;
      administered.&#xD;
&#xD;
      Arm B:&#xD;
&#xD;
      Patients will be treated with additional 4-8 cycles of FLOT. Surgical interventions are&#xD;
      allowed for palliation.&#xD;
&#xD;
      In both of the arms, tumor assessments (CT/MRI or PET of the relevant organs) are performed&#xD;
      prior to randomization and then every 3 months thereafter until progression/relapse, death or&#xD;
      end of follow-up.&#xD;
&#xD;
      Quality of life (QoL) will be assessed at baseline, prior to randomization, and every 3&#xD;
      months after randomization during treatment and in the follow-up phase, together with tumor&#xD;
      assessments.&#xD;
&#xD;
      Survival status and status on relapse/first progress of disease will be assessed every 3&#xD;
      months for up to 5 years after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) adjusted OS</measure>
    <time_frame>up to 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL-response</measure>
    <time_frame>up to 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL mean scores</measure>
    <time_frame>up to 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in patients with lymph node metastases only</measure>
    <time_frame>up to 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical mortality</measure>
    <time_frame>up to 2 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity - Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>From signature of the informed consent form (ICF) up to 30 days after last administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">271</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: FLOT chemotherapy + surgery (OP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles (8 weeks) FLOT pre-OP - surgery - 4-8 cycles FLOT (8-16 weeks) post-OP&#xD;
Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).&#xD;
* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.&#xD;
For HER-2 positive disease, trastuzumab should be added:&#xD;
Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: FLOT chemotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles (8 weeks) FLOT followed by further 4-8 cycles FLOT (8-16 weeks)&#xD;
Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).&#xD;
* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.&#xD;
For HER-2 positive disease, trastuzumab should be added:&#xD;
Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>2600 mg/m², d1 i.v., every 2 weeks</description>
    <arm_group_label>Arm A: FLOT chemotherapy + surgery (OP)</arm_group_label>
    <arm_group_label>Arm B: FLOT chemotherapy alone</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>200 mg/m², d1, i.v., every 2 weeks</description>
    <arm_group_label>Arm A: FLOT chemotherapy + surgery (OP)</arm_group_label>
    <arm_group_label>Arm B: FLOT chemotherapy alone</arm_group_label>
    <other_name>calcium folinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m², d1, i.v., every 2 weeks</description>
    <arm_group_label>Arm A: FLOT chemotherapy + surgery (OP)</arm_group_label>
    <arm_group_label>Arm B: FLOT chemotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>50mg/m², d1, i.v., every 2 weeks</description>
    <arm_group_label>Arm A: FLOT chemotherapy + surgery (OP)</arm_group_label>
    <arm_group_label>Arm B: FLOT chemotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks</description>
    <arm_group_label>Arm A: FLOT chemotherapy + surgery (OP)</arm_group_label>
    <arm_group_label>Arm B: FLOT chemotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium folinate</intervention_name>
    <description>can be used to replace leucovorin (calcium folinate)</description>
    <arm_group_label>Arm A: FLOT chemotherapy + surgery (OP)</arm_group_label>
    <arm_group_label>Arm B: FLOT chemotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Aim of surgical resection is a complete (R0) resection of the primary tumor and the metastases or a complete macroscopic cytoreduction of the metastases.</description>
    <arm_group_label>Arm A: FLOT chemotherapy + surgery (OP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed limited metastatic gastric or GEJ adenocarcinoma.*&#xD;
&#xD;
          2. Medical and technical operability of the primary.&#xD;
&#xD;
          3. Metastatic lesions are resectable or can be controlled by local ablative procedure&#xD;
             (central evaluation).&#xD;
&#xD;
          4. No prior chemotherapy and no prior tumor resection.&#xD;
&#xD;
          5. Female and male patients ≥ 18 years. Patients in reproductive age must be willing to&#xD;
             use adequate contraception during the study and 3 months after the end of the study&#xD;
             (appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal&#xD;
             ligation, vasectomy), hormonal contraception (implantable, patch, oral), and&#xD;
             double-barrier methods (any double combination of: intrauterine device, male or female&#xD;
             condom with spermicidal gel, diaphragm, sponge, cervical cap)). Female patients with&#xD;
             childbearing potential need to have a negative pregnancy test within 7 days before&#xD;
             study start.&#xD;
&#xD;
          6. ECOG (Eastern Cooperative Oncology Group) Performance Status 0 or 1&#xD;
&#xD;
          7. Adequate hematological, hepatic and renal function parameters:&#xD;
&#xD;
               -  Leukocytes ≥ 3000/µl&#xD;
&#xD;
               -  Platelets ≥ 100,000/µl&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x upper limit of normal, or glomerular filtration rate&#xD;
                  (GFR) &gt; 40 ml/min&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x upper limit of normal&#xD;
&#xD;
               -  AST (aspartate aminotransferase) and ALT (alanine transaminase) ≤ 3.5 x upper&#xD;
                  limit of normal&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 6 x upper limit of normal&#xD;
&#xD;
          8. Written informed consent of the patient.&#xD;
&#xD;
        (*) Definition of the limited metastatic status is:&#xD;
&#xD;
          1. Retroperitoneal lymph node metastases (RPLM) (e.g., para-aortal, intra-aorto-caval,&#xD;
             parapancreatic or mesenterial lymph nodes) only (Note: in duodenum invading gastric&#xD;
             cancer, retropancreatic nodes are not regarded M1) or/and&#xD;
&#xD;
          2. at maximum one organ involved with or without RPLM according to the following schema:&#xD;
             I. Localized potentially operable peritoneal carcinomatosis: stage P1 according to&#xD;
             classification of the &quot;Japanese Research Society for Gastric Cancer&quot; (Clinically&#xD;
             visible carcinomatosis of the peritoneum or of the pleura and &gt;P1 peritoneal&#xD;
             carcinomatosis are not allowed!) or II. Liver: maximum of 5 metastatic lesions that&#xD;
             are potentially resectable or III. Lung: unilateral involvement, potentially&#xD;
             resectable or IV. Uni- or bilateral Krukenberg tumors (ovarian met.) in the absence of&#xD;
             macroscopic peritoneal carcinomatosis or V. Uni- or bilateral adrenal gland metastases&#xD;
             or VI. Extra-abdominal lymph node metastases such as supraclavicular or cervical lymph&#xD;
             node involvement or VII. Localized bone involvement (defined as being within one&#xD;
             radiation field) or VIII. Other metastatic disease location that is considered limited&#xD;
             by the investigator and is confirmed by the review committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical inoperability&#xD;
&#xD;
          2. Inability to understand the aims of the study and/or protocol procedures&#xD;
&#xD;
          3. Metastatic disease not fulfilling the criteria of limited disease mentioned in the&#xD;
             inclusion criteria or non-metastatic stage (cM0)&#xD;
&#xD;
          4. Cirrhosis of the liver, pronounced alcohol abuse with anticipated detoxification,&#xD;
             severe pulmonary infection with considerable reduction of pulmonary function&#xD;
&#xD;
          5. Primary not resectable&#xD;
&#xD;
          6. Hypersensitivity to 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, or trastuzumab&#xD;
             (in HER-2 positive tumors)&#xD;
&#xD;
          7. Contraindication versus 5-fluorouracil, leucovorin, oxaliplatin, docetaxel (see&#xD;
             specific product information), or trastuzumab (in HER-2 positive tumors)&#xD;
&#xD;
          8. Clinically significant active coronary heart disease, cardiomyopathy or congestive&#xD;
             heart failure, NYHA (New York Heart Association) III-IV&#xD;
&#xD;
          9. Clinically significant valvular defect&#xD;
&#xD;
         10. Past or current history of other malignancies unless curatively treated and without&#xD;
             evidence of disease for more than 3 years, except for curatively treated basal cell&#xD;
             carcinoma of the skin and in situ carcinoma of the cervix&#xD;
&#xD;
         11. Known brain metastases&#xD;
&#xD;
         12. Other severe internal disease or acute infection&#xD;
&#xD;
         13. Peripheral polyneuropathy &gt; NCI grade II&#xD;
&#xD;
         14. Serious hepatic impairment (AST/ALT&gt;3.5xULN, AP&gt;6xULN, bilirubin&gt;1.5xULN; ULN = upper&#xD;
             limit of normal)&#xD;
&#xD;
         15. Chronic inflammatory bowel disease&#xD;
&#xD;
         16. Any other concurrent antineoplastic treatment including irradiation&#xD;
&#xD;
         17. Participation in another clinical study&#xD;
&#xD;
         18. Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Clinical Cancer Research (IKF), Krankenhaus Nordwest; University Cancer Center Frankfurt (UCT)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Pauligk, PhD</last_name>
    <phone>069 7601</phone>
    <phone_ext>3906</phone_ext>
    <email>pauligk.claudia@khnw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulli S Bankstahl</last_name>
    <phone>069 7601</phone>
    <phone_ext>4596</phone_ext>
    <email>bankstahl.ulli@khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salah-Eddin Al-Batran, MD</last_name>
      <phone>+496976014420</phone>
      <email>albatran@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Pauligk, PhD</last_name>
      <phone>+496976013906</phone>
      <email>pauligk.claudia@khnw.de</email>
    </contact_backup>
    <investigator>
      <last_name>Salah-Eddin Al-Batran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ikf-nordwest.de/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>perioperative</keyword>
  <keyword>FLOT</keyword>
  <keyword>limited metastatic</keyword>
  <keyword>GEJ cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

